Drug Trial Radar · NCT05651932
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
165
Planned (sponsor's estimate)
Start
Feb 22, 2023
Primary completion
Dec 31, 2027
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- K36 Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Bristol-Myers Squibb
- First posted
- Dec 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
Conditions
- Multiple Myeloma
- Myeloma
- Myeloma Multiple
Interventions
Cohort A1 & A2: KTX-1001Drug
KTX-1001: Orally for 28 days each cycle until progression. Dexamethasone: Orally once weekly
Cohort B1 & B2: KTX-1001+MezigdomideDrug
Drug: KTX-1001: Orally for 28 days each cycle until progression Drug: Dexamethasone: Orally once weekly Drug: Mezigdomide Dexamethasone: Orally once weekly
Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)Drug
Drug: KTX-1001: Orally for 28 days each cycle until progression Drug: Dexamethasone: Orally once weekly Drug: Carfilzomib (KYPROLIS®): IV, once weekly for 3 weeks in each 28-day cycle
Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid)Drug
Drug: KTX-1001: Orally for 28 days each cycle until progression Drug: Dexamethasone: Orally once a week Drug: Pomalidomide (Pomalyst, Imnovid): Orally, for 21 days in each 28-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation: Determination of Recommended Phase 2 Dose (RP2D) and/or Maximum Tolerated Dose (MTD) Dose Expansion: Provide preliminary efficacy data on the antitumor effects of KTX-1001 in combination with other anti-myeloma therapyTime frame: Cycle 1 (28 days)
Locations
29 sites in 4 countries. Site status is shown where the registry gives one.
UCSF Medical Center - Hematology and Blood and Marrow Transplant Clinic
San Francisco, California · Recruiting
Mayo Clinic Hospital - Florida
Jacksonville, Florida · Recruiting
University of Miami Don Soffer Clinical Research Center
Miami, Florida · Not yet recruiting
The Winship Cancer Institute of Emory University
Atlanta, Georgia · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Mayo Clinic - Transplant Center - Rochester
Rochester, Minnesota · Recruiting
Hackensack University Medical Center
Hackensack, New Jersey · Recruiting
Memorial Sloan-Kettering Cancer Center
New York, New York · Recruiting
Atrium Health, Levine Cancer Institute
Charlotte, North Carolina · Recruiting
Duke University Hospital
Durham, North Carolina · Recruiting
Cleveland Clinic - Taussig Cancer Institute
Cleveland, Ohio · Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
Medical University of South Carolina (MUSC) - Hollings Cancer Center
Charleston, South Carolina · Recruiting
Tennessee Oncology
Nashville, Tennessee · Recruiting
University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas · Recruiting
Oncology Consultants
Houston, Texas · Recruiting
Northwest Medical Specialties, PLLC
Tacoma, Washington · Recruiting
Cross Cancer Institute
Edmonton, Alberta, Canada · Not yet recruiting
University Health Network (UHN) - Princess Margaret Cancer Centre (Princess Margaret Hospital)
Toronto, Ontario, Canada · Recruiting
Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hotel-Dieu
Nantes, France · Recruiting
Centre Hospitalier Universitaire de Poitiers (CHU de Poitiers)
Poitiers, France · Recruiting
Institut Universitaire du Cancer de Toulouse - Oncopole
Toulouse, France · Recruiting
Universitaire de Lille
Villeneuve-d'Ascq, France, France · Recruiting
Hospital ClÃ-nic de Barcelona
Barcelona, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
Instituto de Investigacion Biomedica de Salamanca (IBSAL)
Salamanca, Spain · Recruiting
Clínica Universidad de Navarra
Pamplona, Navarre, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.